Cancer medicine · 2026
Association of Combined MET/HGF Expression With the Colorectal Cancer Immune Microenvironment: An Integrated Immunohistochemical and Multi-Database Analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luo Shuai, Guo Hongwei, Li Xiangli, Long Yiyan, Xin Zepeng, Cheng Yanli
Аннотация
OBJECTIVE: To validate c-MET protein expression in colorectal cancer (CRC) and assess whether joint MET and hepatocyte growth factor (HGF) transcript expression provides descriptive information on tumor microenvironment features beyond MET alone.
METHODS: c-MET protein expression was evaluated by immunohistochemistry in 51 paired CRC and adjacent tissues. The Cancer Genome Atlas (TCGA) and TNMplot datasets assessed MET mRNA expression and clinicopathological associations; Kaplan-Meier Plotter evaluated unadjusted survival; and TIMER (Tumor Immune Estimation Resource) examined purity-adjusted immune correlations. In TCGA colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ) cohorts, samples were divided using cohort-specific median MET and HGF expression. ESTIMATE (Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data) and CIBERSORT (Cell-type Identification by Estimating Relative Subsets of RNA Transcripts) compared inferred tumor purity, immune/stromal scores, and immune-cell composition. These computational estimates were not experimentally validated in this study.
RESULTS: MET mRNA was elevated in CRC datasets, and c-MET protein H-scores were higher in CRC than in paired adjacent tissues. MET expression was not associated with the tested clinicopathological variables. High MET expression was associated with shorter overall and relapse-free survival in unadjusted analyzes. In both cohorts, the MET-high/HGF-low group generally showed higher estimated tumor purity and lower immune and stromal scores, whereas the MET-low/HGF-high group showed the converse pattern. Individual immune-cell subset differences were cohort dependent.
CONCLUSION: MET mRNA and c-MET protein are elevated in CRC. Joint MET/HGF expression may complement MET-only analysis by retaining discordant patterns associated with inferred tumor-cell and immune/stromal composition. These retrospective, algorithm-derived findings do not establish independent prognostic value, HGF/c-MET pathway activation or causality, or a basis for clinical patient stratification.
METHODS: c-MET protein expression was evaluated by immunohistochemistry in 51 paired CRC and adjacent tissues. The Cancer Genome Atlas (TCGA) and TNMplot datasets assessed MET mRNA expression and clinicopathological associations; Kaplan-Meier Plotter evaluated unadjusted survival; and TIMER (Tumor Immune Estimation Resource) examined purity-adjusted immune correlations. In TCGA colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ) cohorts, samples were divided using cohort-specific median MET and HGF expression. ESTIMATE (Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data) and CIBERSORT (Cell-type Identification by Estimating Relative Subsets of RNA Transcripts) compared inferred tumor purity, immune/stromal scores, and immune-cell composition. These computational estimates were not experimentally validated in this study.
RESULTS: MET mRNA was elevated in CRC datasets, and c-MET protein H-scores were higher in CRC than in paired adjacent tissues. MET expression was not associated with the tested clinicopathological variables. High MET expression was associated with shorter overall and relapse-free survival in unadjusted analyzes. In both cohorts, the MET-high/HGF-low group generally showed higher estimated tumor purity and lower immune and stromal scores, whereas the MET-low/HGF-high group showed the converse pattern. Individual immune-cell subset differences were cohort dependent.
CONCLUSION: MET mRNA and c-MET protein are elevated in CRC. Joint MET/HGF expression may complement MET-only analysis by retaining discordant patterns associated with inferred tumor-cell and immune/stromal composition. These retrospective, algorithm-derived findings do not establish independent prognostic value, HGF/c-MET pathway activation or causality, or a basis for clinical patient stratification.